The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Micronised progesterone (Utrogestan®) has been accepted for adjunctive use with oestrogen in post-menopausal women with an intact uterus, as hormone replacement therapy (HRT). This product provides an additional treatment choice in the therapeutic class of progestogens.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.